Revenue
2012
2013
2014
2019
2020
2021
2022
2023
SELLAS Life Sciences Group, Inc. (SLS)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2013
2014
2015
2016
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1.0M | $7.6M | $1.9M | $0 | — | — | — | — | $9.3M | $2.5M | $0 | $0 | — |
| Research & development | $16.0M | $19.1M | $24.0M | $20.3M | $15.7M | $9.3M | $7.3M | $8.8M | $6.1M | $19.9M | $23.6M | $27.7M | $20.4M | $14.6M | $3.9M | $6.0M |
| Operating expenses | — | — | — | — | — | — | — | — | — | $31.9M | $34.2M | $43.9M | $28.5M | $21.2M | $12.5M | $16.6M |
| Operating income | −$28.3M | −$31.5M | −$37.9M | −$42.0M | −$25.3M | −$17.0M | −$20.0M | — | −$23.0M | −$16.0M | −$34.2M | −$43.9M | −$28.5M | −$21.2M | −$12.5M | — |
| EBITDAderived | — | — | — | — | — | — | — | — | — | −$16.0M | −$34.1M | −$43.8M | −$28.2M | −$21.1M | −$12.3M | — |
| Net income | −$26.9M | −$30.9M | −$37.3M | −$41.3M | −$20.7M | −$16.8M | −$19.3M | −$27.7M | −$23.8M | −$17.7M | −$63.9M | −$36.6M | −$76.7M | −$35.0M | −$11.5M | −$12.0M |
| Basic EPSper diluted share | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | -$2.11 | -$10.92 | -$157.72 | -$10.44 | -$18.66 | -$8.23 | -$6.13 | -$0.85 | -$0.56 | -$0.32 | -$0.67 |
| Diluted EPSper diluted share | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | -$2.11 | -$10.92 | -$157.72 | -$10.44 | -$18.66 | -$8.23 | -$6.13 | -$0.85 | -$0.56 | -$0.32 | -$0.67 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 19, 2025Form 4 | Kalin Katherine BachDirector | BuyCommon Stock | 63.4K | $1.59 | $100.8K | 104.4K |
| Jun 12, 2025Form 4 | VAN NOSTRAND ROBERT LDirector | BuyCommon Stock | 10.0K | $1.48 | $14.8K | 20.4K |
| May 30, 2025Form 4 | Wasman JaneDirector | BuyCommon Stock | 20.0K | $1.69 | $33.8K | 30.4K |
| May 22, 2025Form 4 | Kalin Katherine BachDirector | BuyCommon Stock | 20.0K | $1.80 | $36.0K | 41.0K |